PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions. (PubMed, Front Med (Lausanne)) - Oct 11, 2026 - "Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [177Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival (rPFS) establishing PSMA-targeted RLT as a key treatment option in advanced disease...This review provides a comprehensive overview of the major developments in the field, including advances in molecular imaging, emerging therapeutic indications, combination approaches, and future directions in PSMA-targeted theranostics according to recent clinical trial data. Collectively, these developments highlight the evolving role of beta-emitting RLT across the prostate cancer disease."
Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
Adam Bekkhoucha; Alessia Daverio; Alexandre Megherbi; Alice Bernard Tessier; Anna Patrikidou; Camilo Garcia; Cédric Pobel; Désirée Deandreis; Hiba Noamen; Jacopo Uliano; Khali Trabelsi; Laurence Albiges; Lison Ferreol; Macarena Rey-Cardenas; Mario DiPalma; Mario Terlizzi; Mehdi Borsali; Natacha Naoun; Pierre Blanchard; Ronan Flippot; Solenn Barraud; Yohann Loriot
|